The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile ...

A novel tool created by researchers at Weill Cornell Medicine and the University of Adelaide has improved the capacity to ...

A UMAP graphical depiction of 45,963 cancer cells from patients whose chronic lymphocytic leukemia has transformed into a more aggressive type. The different colors represent different cell states (e.

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...